Form 4: GE HealthCare Technologies Inc. Executive Taha Kass-Hout Reports Stock and Option Awards
SEC Form 4 Filing
Chief Technology Officer Taha Kass-Hout reports acquisition of restricted stock units and employee stock options in GE HealthCare Technologies Inc.
Summary
- Taha Kass-Hout, Chief Technology Officer of GE HealthCare Technologies Inc., filed a Form 4 detailing changes in beneficial ownership.
- On March 3, 2025, Kass-Hout was awarded 11,567 restricted stock units (RSUs) and an employee stock option for 33,079 shares.
- The RSUs will vest in three tranches: 33% on September 3, 2026, 33% on September 3, 2027, and 34% on September 3, 2028.
- The employee stock options also vest in three tranches: 33% exercisable on September 3, 2026, 33% on September 3, 2027, and 34% on September 3, 2028, subject to certain conditions.
- The exercise price for the employee stock options is $86.45.
- Following these transactions, Kass-Hout directly owns 68,272 shares of GE HealthCare common stock and options for 33,079 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management interests with shareholders.
Positives
- The grant of RSUs and stock options aligns the executive's interests with those of the shareholders, incentivizing long-term performance.
- The vesting schedule encourages continued service and commitment from the Chief Technology Officer.
Industry Context
Stock and option awards are a common practice in the healthcare technology industry to attract, retain, and incentivize key executives.
Comparison to Industry Standards
- Executive compensation packages in the healthcare technology sector typically include a mix of base salary, bonus, stock options, and restricted stock units.
- Companies like Siemens Healthineers and Philips also utilize similar equity-based compensation plans for their top executives.
- The vesting schedules are fairly standard, aligning with industry norms for retention and performance incentives.
Stakeholder Impact
- The stock and option awards could have a slightly dilutive effect on existing shareholders.
- The awards incentivize the Chief Technology Officer to drive innovation and growth, potentially benefiting shareholders in the long term.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of transaction: Award of restricted stock units and employee stock options. |
| 03/05/2025 | Date of Form 4 filing. |
| 09/03/2026 | First vesting date for 33% of restricted stock units and employee stock options. |
| 09/03/2027 | Second vesting date for 33% of restricted stock units and employee stock options. |
| 09/03/2028 | Final vesting date for 34% of restricted stock units and employee stock options. |
| 03/03/2035 | Expiration date of the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.